Summary
The latent reservoir of HIV persists for decades in people living with HIV (PWH) on antiretroviral therapy (ART). To determine if persistence arises from the natural dynamics of memory CD4+ T cells harboring HIV, we compared the clonal dynamics of HIV proviruses to that of memory CD4+ T cell receptors (TCRβ) from the same PWH and from HIV-seronegative people. We show that clonal dominance of HIV proviruses and antigen-specific CD4+ T cells are similar but that the field’s understanding of the persistence of the less clonally dominant reservoir is significantly limited by undersampling. We demonstrate that increasing reservoir clonality over time and differential decay of intact and defective proviruses cannot be explained by mCD4+ T cell kinetics alone. Finally, we develop a stochastic model of TCRβ and proviruses that recapitulates experimental observations and suggests that HIV-specific negative selection mediates approximately 6% of intact and 2% of defective proviral clearance. Thus, HIV persistence is mostly, but not entirely, driven by natural mCD4+ T cell kinetics.
Competing Interest Statement
MJP reports participation on a data safety and monitoring board for American Gene Technologies.
Funding Statement
This research was funded in part by awards (AA, KS, DBR) from the Johns Hopkins University Center for AIDS Research and the University of Washington/Fred Hutch Center for AIDS Research, NIH funded programs (P30AI094189, P30AI02775), which are supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIA, NIGMS, NIDDK, NIMHD. This research was also funded in part by the NIH (grants K25AI155224 - DBR, R01AI150500 JTS, K08AI143391 AA, K23AI157875 MJP, UM1AI126620 LJM, P30AI094189 FRS, UM1 AI164566 FRS, U01 AI177211 FRS, DP5OD031834 FRS), the W.W. Smith Charitable Trust (AA), the Pearl M. Stetler Foundation (AA), and the Robert I. Jacobs Fund of The Philadelphia Foundation (LJM). LJM is supported by the Herbert Kean, M.D., Family Professorship. RS is a Howard Hughes Medical Institute (HHMI) Fellow. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committees/IRBs of the Johns Hopkins University School of Medicine, the University of California San Francisco, and the University of Pennsylvania gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work will be freely available at the time of peer reviewed publication.
https://clients.adaptivebiotech.com/pub/deneuter-2018-cmvserostatus
